2,914 material Form 8-K filings that 2,352 companies we cover made with the SEC in August 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
InnSuites Hospitality Trust reported a record July 2026 revenue total of $597,323 for its two hotels, the highest July total ever for the two hotels combined. Shareholders also voted at the August 12, 2026 annual meeting, electing Steven S. Robson as trustee and ratifying the BCRG Group as independent accountants. The trust said it continues to seek a reverse merger partner.
July 2026 revenue for the two hotels combined: $597,323, the highest July total ever
Total revenues for fiscal first half 2027 (February 1 to July 31, 2026) exceeded $4.1 million
Steven S. Robson trustee vote: 7,090,809 for, 25,817 against, 414,669 abstentions
BCRG Group ratification: 7,447,535 for, 23,936 against, 59,824 abstentions; BCRG recently merged with Simon & Edward, LLP
Enova subsidiary NetCredit LOC Receivables 2024 amended its credit facility, raising the revolving commitment from $200 million to $300 million, extending the revolving period to February 21, 2029, extending maturity to February 21, 2030, and lowering the borrowing rate from SOFR + 5.50% to SOFR + 5.00%. Separately, an indirect subsidiary priced $300,886,000 of 2026-A Notes backed by unsecured consumer installment loans, with closing expected on or about August 21, 2026; the notes are not guaranteed by Enova.
Revolving commitment increases from $200 million to $300 million, with the revolving period extended to February 21, 2029.
Borrowing rate decreases from SOFR + 5.50% to SOFR + 5.00%; maturity extended from February 21, 2028 to February 21, 2030.
2026-A Notes total $300,886,000: Class A $240,709,000 at 5.88%, Class B $44,341,000 at 7.68%, Class C $15,836,000 at 10.64%.
Notes are priced subject to market conditions, with anticipated closing on or about August 21, 2026; they are offered only to qualified institutional buyers and certain non-U.S. persons.
Reading International reported second-quarter 2026 total revenue of $66.9 million, up 11% from $60.4 million a year earlier, and net income of $2.3 million, compared with a net loss of $2.8 million in Q2 2025. Basic earnings were $0.10 per share, against a loss of $0.12 per share a year earlier. Short-term debt rose sharply to $108.0 million as several loans come due within twelve months, and cash was $5.7 million at June 30, 2026, so shareholders will be watching how those obligations are refinanced.
Q2 2026 total revenue of $66.9 million rose 11% from $60.4 million in Q2 2025, the highest second-quarter revenue since Q2 2019.
Q2 2026 net income was $2.3 million, versus a net loss of $2.8 million in Q2 2025; basic earnings per share were $0.10 versus a loss of $0.12.
Short-term debt net of deferred finance costs was $108.0 million at June 30, 2026, up $72.0 million from December 31, 2025, mainly because Trust Preferred Securities and Emerald Creek Capital loans become due within twelve months.
Cash and cash equivalents were $5.7 million at June 30, 2026; the Bank of America facility maturity was extended to December 21, 2026, and the Santander loan to October 1, 2026.
PAVmed reported results for the quarter ended June 30, 2026, with a GAAP net loss attributable to common stockholders of $5.5 million, or $(0.87) per diluted share, compared with a loss of $13.3 million, or $(22.08) per share, a year earlier. The company also gave a business update on subsidiaries Lucid Diagnostics and Veris Health, including a first laboratory benefit manager coverage policy for EsoGuard.
GAAP net loss attributable to common stockholders was $5.5 million, or $(0.87) per diluted share, for the three months ended June 30, 2026, versus $13.3 million, or $(22.08) per share, a year earlier.
Non-GAAP adjusted loss was $1.7 million, or $(0.27) per share, for the quarter; cash and cash equivalents were $3.8 million as of June 30, 2026, up from $1.5 million at December 31, 2025.
Lucid Diagnostics recognized $1.5 million in EsoGuard revenue for the second quarter and processed 2,770 EsoGuard tests.
Veris Health is targeting an early 2027 FDA 510(k) submission for its implantable physiological monitor.
Greenland Technologies reported unaudited results for the quarter ended June 30, 2026, in a press release furnished as Exhibit 99.1. Second-quarter revenue rose 37.6% to $29.9 million, and the company returned to profit, with net income of $4.9 million compared with a net loss of $2.8 million a year earlier. Earnings per share were $0.13 versus a loss of $0.20, and the filing gives no guidance for future periods.
Q2 revenue $29.9 million, up 37.6% from $21.7 million; sales volume up 24.1% to 53,243 sets
Q2 gross margin 31.9%, up from 26.5%; income from operations $6.0 million versus a $2.3 million loss
Net income attributable to shareholders $3.5 million; basic and diluted EPS $0.13 versus a $0.20 loss
First-half revenue $55.4 million, up 27.7%; cash and equivalents $8.98 million at June 30, 2026
Boost Run reported second-quarter 2026 results, its first as a public company after a May 8, 2026 business combination. Revenue for the quarter was $31.1 million, up from $8.4 million a year earlier, and total long-term contracted revenue stands at $1.9 billion. The filing does not disclose net income or earnings per share for the quarter.
Q2 2026 total revenue was $31.1 million, up 270% from $8.4 million in the prior-year period.
Total long-term contracted revenue stands at $1.9 billion, with over $1 billion in contracts signed during the quarter.
Unrestricted cash was $120.2 million at June 30, 2026, including $114.1 million in net proceeds from the business combination.
Targets include about $400 million in annualized recurring revenue at the end of fiscal 2026 and a net cash flow margin of 15% to 20% in forward periods.
Replimune reported a fiscal first-quarter 2027 net loss of $69.8 million, or $0.72 per share, down from $86.7 million, or $0.95 per share, a year earlier, as research and development and selling, general and administrative expenses both fell. The company also said the FDA granted accelerated approval for TUDRIQEV on August 6, 2026, and expects product in the market within 60 days, while cash declined to $195.3 million at June 30, 2026.
Net loss was $69.8 million ($0.72 per share) for the quarter ended June 30, 2026, versus $86.7 million ($0.95 per share) a year earlier.
R&D expenses were $49.3 million versus $57.8 million, and SG&A expenses were $19.0 million versus $32.6 million.
Cash, cash equivalents and short-term investments were $195.3 million at June 30, 2026, down from $268.9 million at March 31, 2026; the company cites $141.0 million in net proceeds from an August 2026 stock issuance.
The FDA granted accelerated approval for TUDRIQEV on August 6, 2026; Michelle DiNapoli was appointed Chief Commercial Officer, effective August 18, 2026.
Neumora reported a second-quarter 2026 net loss of $43.1 million, down from $52.7 million a year earlier, as research and development and general and administrative expenses declined. On the same day, President Joshua Pinto became chief executive officer effective August 14, 2026, succeeding Paul L. Berns, who becomes Executive Chairperson. The company said its $116.8 million in cash and cash equivalents is expected to support operations into the third quarter of 2027.
Q2 2026 net loss was $43.1 million, compared with $52.7 million in Q2 2025.
R&D expense was $29.3 million (Q2 2025: $38.7 million); G&A expense was $12.9 million (Q2 2025: $15.3 million).
Joshua Pinto, Ph.D., succeeds Paul L. Berns as CEO effective August 14, 2026, and was appointed a Class III director.
Cash and cash equivalents were $116.8 million as of June 30, 2026, expected to fund operations into the third quarter of 2027.
Teamshares reported second-quarter 2026 revenue of $148.7 million, up 20% from a year earlier, and net income of $9.5 million compared with a $12.9 million loss in the same period of 2025. The company reaffirmed its 2026 guidance of $60 million in Pro Forma Adjusted EBITDA, which assumes it completes transactions that provide additional capital for acquisitions. The net income improvement was helped by a non-cash $24.9 million gain from changes in the fair value of earnout share and deferred founder share liabilities.
Q2 2026 revenue was $148.7 million, up $25.1 million (20%) year over year; diluted EPS was $0.16 versus a $(0.26) loss a year earlier.
Adjusted EBITDA was $9.6 million, up $6.0 million (166%); Pro Forma Adjusted EBITDA was $9.8 million.
Full-year 2026 Pro Forma Adjusted EBITDA guidance of $60 million was reaffirmed, contingent on securing additional acquisition financing.
Non-binding letters of intent cover 10 businesses with about $30 million in annual EBITDA; a non-binding term sheet for a senior secured warehouse facility was entered on August 4, 2026.
ACCO Brands agreed to acquire Trust, a European computer and gaming accessories provider, from Egeria in a deal valued at approximately $57 million. The company says the deal extends its technology peripherals business, which would reach about $500 million in annual sales on a pro forma basis.
Deal value is approximately $57 million; Trust generates approximately $100 million in annual revenue.
Trust is expected to be modestly accretive to adjusted EPS in the first 12 months; cost synergies of approximately $5 to $8 million are expected within 18 months after closing.
Financing will come from borrowings under ACCO Brands' revolving credit facility; closing is expected in late third quarter or early fourth quarter 2026, subject to competition authority approvals.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.